Loading
NASDAQHealthcareBiotechnology
Latest quote
$11.30
+$0.42 · +3.86%
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Previous close
$11.30
+$0.42 · +3.86%
Regular session · ET · Market data may be delayed.
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Day range
Current $11.30
52-week range
Current $11.30
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
58
Mixed
Risk
69
High Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Day range
Current $11.30
52-week range
Current $11.30
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 2.82M USD | 6.98M USD | 8.02M USD | 9.56M USD | 9.13M USD |
| Selling, general, and administrative | 9.28M USD | 9.66M USD | 11.36M USD | 13.53M USD | 8.08M USD |
| Operating expenses | 17.28M USD | 21.64M USD | 16.81M USD | 23.09M USD | 17.21M USD |
| Interest income | 1K USD | 8K USD | 82K USD | 45.94K USD | 10.6K USD |
| Interest expense | 949K USD | −244K USD | — | — | — |
| Depreciation and amortization | — | 14K USD | 4K USD | 4K USD | 4.13K USD |
| Operating income | −17.28M USD | −21.64M USD | −16.81M USD | −23.09M USD | −17.21M USD |
| Net income | −17.3M USD | −19.79M USD | −10.01M USD | −17.75M USD | −17.42M USD |
Company facts updated Sep 13, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$30.00
165.49% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Mar 31, 2026 | 1:40 | — | — |
Stock split | Aug 17, 2023 | 1:20 | — | — |
Stock split | Sep 17, 2015 | 1:10 | — | — |
Stock split | Jan 3, 2014 | 1:5 | — | — |
Effective Mar 31, 2026
1:40
Effective Aug 17, 2023
1:20
Effective Sep 17, 2015
1:10
Effective Jan 3, 2014
1:5
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
